TELO (Telomir Pharmaceuticals, Inc.) Future Price to Earnings

Official company branding of Telomir Pharmaceuticals, Inc. (TELO)

Telomir Pharmaceuticals (TELO) is in the early stages of research, remaining insulated from market cycles. A forward P/E ratio chart for the company is available in the GURU.Markets system, where 0.00 represents the current metric. Success in telomere-based rejuvenation will ensure absolute pricing power, while breakthrough small molecule developments will enable the halting of aging processes.

telomirpharma.com - TELO Market Cap to Future Earnings Ratio (period 02/21/2024 - 11/17/2026)

Summary analytical data breakdowns for telomirpharma.com (TELO)

- current price and projected stock value:
Brand item of Telomir Pharmaceuticals

To find fundamental support for Telomir Pharmaceuticals (TELO) shares, it is essential to consider the diversification of research into telomeric compounds aimed at combating age-related pathologies. By analyzing the company's future P/E trajectory, an investor compares current market capitalization with expected annual earnings, which allows for an assessment of the asset's overbought status and the determination of a safe entry volume to avoid risking price destabilization.

Key competitors

Future Price to Earnings haleon.com (HLN)|KVUE (Kenvue Health) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma PLC VRNA|Jyong Biotech (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|Amneal - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech Corp - Future Price to Earnings Multiple|LQDA (Liquidia Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio glpg.com GLPG|Future Price to Earnings ANI Pharmaceuticals, Inc. (ANIP)|MNKD (MannKind Corp) - Future Price to Earnings Multiple|Forward P/E Multiple AMPH (Amphastar Pharmaceuticals Inc)|PCRX (Pacira) - Price to Expected Earnings Ratio|SPRY - Future Price to Earnings|Future Price to Earnings Multiple TBPH (Theravance Biopharma)|AQST (aquestive.com) - Projected Price to Earnings|Price to Expected Earnings Ratio SCPH (scPharmaceuticals, Inc.)|Projected Price to Earnings TECX|Tonix Pharmaceuticals (TNXP) - Market Cap to Projected Earnings|Forward P/E Multiple SXTC|Forward P/E Multiple Eupraxia Pharma (EPRX)|Future Price to Earnings BioHarvest Sciences Inc. BHST|EXOZ - Projected Price to Earnings|ORMP: Projected Price to Earnings|Future Price to Earnings Multiple ENTX (enterabio.com)|MindWalk Therapeutics (HYFT) - Future Price to Earnings|Projected Price to Earnings Ratio abvcpharma.com (ABVC)|Future Price to Earnings Cumberland Pharma|Future Price to Earnings QNTM|Forward P/E Multiple FGEN|Forward P/E Multiple Rani Therapeutics Holdings (RANI)|Forward P/E Multiple SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Projected Price to Earnings Ratio|LEXX - Future Price to Earnings|PULM (Pulmatrix) - Price to Future Earnings Ratio|Pheton Holdings Ltd (PTHL) - Future Price to Earnings|Aptorum - Future Price to Earnings Multiple|Projected Price to Earnings LYRA|Projected Price to Earnings Impact BioMedical Inc (IBO)|Forward P/E Multiple TNFA|YCBD: Price to Expected Earnings Ratio|Future Price to Earnings PainReform PRFX|altamiratherapeutics.com (CYTO) - Projected Price to Earnings Ratio|LIPO: Projected Price to Earnings|OPTN (optinose.com) - Price to Future Earnings Ratio|PIRS: Forward P/E Multiple|PROC - Market Cap to Projected Earnings|PTPI (Petros Pharma) - Forward P/E Multiple|Future Price to Earnings QLI|Forward P/E Multiple SLRN|Market Cap to Future Earnings Ratio TFFP